同伴主导行为干预对急诊科阿片类药物过量高风险患者的效果:一项随机临床试验
该随机临床试验自2018年11月15日至2021年5月31日从2个急诊科招募648例因阿片类药物过量就诊、接受阿片类药物使用障碍相关治疗或近期有过量史的患者,随机接受认证同伴康复专家行为干预(n=323)或医院雇用的持证临床社会工作者提供的标准干预(n=325),同伴组干预后提供最多90天持续联系。主要终点为入组30天内通过全州行政数据库确定性链接评估的物质使用障碍治疗参与(入住正式公共许可治疗项目或接受诊室阿片类药物使用障碍药物治疗)。结果显示干预组103/323例(32%)、常规组98/325例(30%)在30天内接受治疗;最常使用的是门诊丁丙诺啡(119例,18.4%)、美沙酮(44例,6.8%)和住院治疗(44例,6.8%)。作者认为急诊科行为干预可能有效促进治疗参与,但实施者身份对短期结局影响较小,需进一步研究长期结局。
要点
- 648例阿片类药物过量高风险急诊患者随机接受同伴康复专家行为干预(n=323)或持证临床社会工作者标准干预(n=325)。
- 30天内物质使用障碍治疗参与率:同伴组103/323例(32%)vs 常规组98/325例(30%)。
- 全体参与者中最常接受的治疗为门诊丁丙诺啡119例(18.4%)、美沙酮44例(6.8%)和住院治疗44例(6.8%)。
- 同伴康复专家须有至少2年康复经历、完成45小时培训并具备500小时监督下工作经验,干预后提供最多90天持续联系。
- 作者认为急诊科行为干预可能有效促进治疗参与,但实施者身份对短期结局影响可能较小;需进一步研究长期治疗参与及其他健康结局(如反复过量)。
适用人群与场景
- 因阿片类药物过量到急诊就诊、正在接受阿片类药物使用障碍相关治疗或被识别为近期有过量史的患者。
- 年龄均值(标准差)36.9(10.8)岁;男性442例(68.2%),白人444例(68.5%)。
诊断标准与关键阈值
- 物质使用障碍治疗参与定义:首次急诊就诊后30天内入住正式、公共许可的物质使用障碍治疗项目或接受诊室阿片类药物使用障碍药物治疗。
- 治疗参与通过全州行政数据库确定性链接评估。
研究设计与关键结果
- 研究类型:随机临床试验,自2018年11月15日至2021年5月31日从2个急诊科招募648例患者。
- 干预:认证同伴康复专家行为干预(n=323)vs 医院雇用的持证临床社会工作者提供的标准干预(n=325);同伴康复专家为至少有2年康复经历、完成45小时培训并具备500小时监督下工作经验者,干预后提供最多90天持续联系。
- 主要终点:30天内物质使用障碍治疗参与率干预组103/323例(32%)vs 常规组98/325例(30%)。
- 全体参与者中最常接受的治疗:门诊丁丙诺啡119例(18.4%)、美沙酮44例(6.8%)、住院治疗44例(6.8%)。
证据类型、等级与局限
- 证据类型:随机临床试验。
- 局限:作者指出需进一步研究以确定对长期物质使用障碍治疗参与及其他健康结局(如反复过量)的影响。
对床旁实践的改变
- 作者认为急诊科行为干预可能有效促进物质使用障碍治疗参与,但实施者身份对短期结局影响可能较小。
- 作者指出需进一步研究以确定对长期物质使用障碍治疗参与及其他健康结局(如反复过量)的影响。
指南或共识出处
- 临床试验注册号:ClinicalTrials.gov NCT03684681。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Fatal and nonfatal opioid overdoses are at record levels, and emergency department (ED) visits may be an opportune time to intervene. Peer-led models of care are increasingly common; however, little is known about their effectiveness.
OBJECTIVE: To evaluate the effect of a peer-led behavioral intervention compared with the standard behavioral intervention delivered in the ED on engagement in substance use disorder (SUD) treatment within 30 days after the ED encounter.
DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial recruited 648 patients from 2 EDs from November 15, 2018, to May 31, 2021. Patients were eligible to participate if they were in the ED for an opioid overdose, receiving treatment related to an opioid use disorder, or identified as having had a recent opioid overdose.
INTERVENTIONS: Participants were randomly assigned to receive a behavioral intervention from a certified peer recovery specialist (n = 323) or a standard intervention delivered by a hospital-employed licensed clinical social worker (n = 325). A certified peer recovery specialist was someone with at least 2 years of recovery who completed a 45-hour training program and had 500 hours of supervised work experience. After the ED intervention, the certified peer recovery specialists offered continued contact with participants for up to 90 days.
MAIN OUTCOMES AND MEASURES: The primary outcome was receipt of SUD treatment within 30 days of enrollment, assessed with deterministic linkage of statewide administrative databases. Treatment engagement was defined as admission to a formal, publicly licensed SUD treatment program or receipt of office-based medication for opioid use disorder within 30 days of the initial ED visit.
RESULTS: Among the 648 participants, the mean (SD) age was 36.9 (10.8) years, and most were male (442 [68.2%]) and White (444 [68.5%]). Receipt of SUD treatment occurred for 103 of 323 participants (32%) in the intervention group vs 98 of 325 participants (30%) in the usual care group within 30 days of the ED visit. Among all participants, the most accessed treatments were outpatient medication for opioid use disorder (buprenorphine, 119 [18.4%]; methadone, 44 [6.8%]) and residential treatment (44 [6.8%]).
CONCLUSIONS AND RELEVANCE: Overall, this study found that a substantial proportion of participants in both groups engaged in SUD treatment within 30 days of the ED visit. An ED-based behavioral intervention is likely effective in promoting treatment engagement, but who delivers the intervention may be less influential on short-term outcomes. Further study is required to determine the effects on longer-term engagement in SUD care and other health outcomes (eg, recurrent overdose).
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03684681.
参考来源
- Beaudoin FL, Jacka BP, Li Y, et al. Effect of a Peer-Led Behavioral Intervention for Emergency Department Patients at High Risk of Fatal Opioid Overdose: A Randomized Clinical Trial. JAMA Netw Open. 2022. PMID: 35943744. doi:10.1001/jamanetworkopen.2022.25582
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。